Preclinical characterization of a novel vaccine for prevention of Chikungunya

预防基孔肯雅热的新型疫苗的临床前表征

• 批准号: 10026738
• 金额: $ 63.68万
• 依托单位: ACTIVIROSOMES LIMITED
• 依托单位国家: 英国
• 项目类别: Small Business Research Initiative
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10026738
• 关键词: Preclinical; characterization; novel; vaccine; prevention

Chikungunya virus is prevalent in more than 200 countries worldwide. Although infection causes illness that is usually non-lethal, it is responsible for development of arthralgia which leaves patient(s) debilitated and sometimes permanently unable to work or perform day-to-day functions. Thus it affects quality of life and causes significant economic losses.Active Virosome Technology" enables intracellular delivery of multiple mRNA molecules efficiently for use as vaccines. We have used it to develop novel vaccine agents for prevention of Chikungunya virus infection which induced a strong immune response, to proof of concept stage.This project undertakes preclinical characterization of our lead chikungunya vaccine candidate.

基孔肯雅病毒在全球200多个国家流行。虽然感染引起的疾病通常是非致命的，但它会导致关节痛的发展，使患者虚弱，有时永久无法工作或执行日常功能。因此，它影响了生活质量，并造成重大的经济损失。"活性病毒体技术”使多种mRNA分子的细胞内输送有效地用作疫苗。我们已经用它来开发新的疫苗制剂，用于预防基孔肯雅病毒感染，诱导强烈的免疫反应，到概念验证阶段。该项目承担我们的主要基孔肯雅疫苗候选人的临床前表征。